Aveir Leadless Pacemaker: Novel Technology With New Anesthetic Implications.
J Cardiothorac Vasc Anesth
; 36(12): 4501-4504, 2022 12.
Article
em En
| MEDLINE
| ID: mdl-36064652
The Aveir VR Leadless Pacemaker (Abbott, Chicago, IL) recently was approved by the US Food and Drug Administration, and joined the Micra (Medtronic, Minneapolis, MN) transcatheter pacing system in the realm of nontransvenous cardiovascular implantable devices. The Aveir VR offers design improvements over its predecessor, the Nanostim (St. Jude Medical). There are recommendations for the perioperative management of conventional transvenous pacemakers, but leadless pacemakers add a new layer of consideration. Although there have been prior documented experiences with the Micra device, there are enough differences between the Aveir VR and the Micra that it is important to understand what makes the Aveir VR unique if an anesthesiologist were to come across one preoperatively.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Marca-Passo Artificial
/
Anestésicos
Limite:
Humans
Idioma:
En
Revista:
J Cardiothorac Vasc Anesth
Ano de publicação:
2022
Tipo de documento:
Article